Sarepta Therapeutics Inc

NASDAQ:SRPT   2:06:56 PM EDT
107.97
-0.68 (-0.63%)
Other Pre-Announcement

Sarepta Therapeutics Inc - QTRLY GAAP Net Loss Of $231.5 Million, Or $2.65 Per Basic And Diluted Share

Published: 08/02/2022 21:26 GMT
Sarepta Therapeutics Inc (SRPT) - Sarepta Therapeutics - Increased Full-year Total Revenue and Net Product Revenue Guidance to a Range of $905-$920 Million and $825-$840 Million, Respectively.
Total Revenues for Q2 2022 Totaled $233.5 Million.
Qtrly GAAP Net Loss of $231.5 Million, Or $2.65 per Basic and Diluted Share.
Qtrly Non-GAAP Net Loss $1.18 per Basic and Diluted Share.
Q2 Earnings per Share View $-1.18, Revenue View $220.8 Million -- Refinitiv Ibes Data (analyst estimates).
FY2022 Revenue View $899.9 Million -- Refinitiv Ibes Data (analyst estimates).